- Home
- MHF vs SGMT Comparison
MHF vs SGMT Comparison
Compare MHF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MHF | SGMT |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.1M | 164.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MHF | SGMT |
|---|---|---|
| Price | $6.87 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 53.5K | ★ 352.1K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,523.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.61 | $1.73 |
| 52 Week High | $7.83 | $11.41 |
Technical Indicators
Market Signals| Indicator | MHF | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 41.75 |
| Support Level | $6.85 | $4.97 |
| Resistance Level | $7.02 | $6.49 |
| Average True Range (ATR) | 0.06 | 0.34 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 11.11 | 7.02 |
Price Performance
Historical ComparisonAbout MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.